Brand name
Tenormin, the original
We didn’t find a savings card or cash price from Tenormin’s maker. Ask the pharmacy for Tenormin’s cash price. With insurance, ask what your plan charges.
Generic name: atenolol
Used for: High blood pressure · Chest pain from heart disease (angina) · Lowering the risk of death from a heart attack · 2 more
From
$4 for 30 tablets, any strength
Generic atenolol at Walmart
Rather have it mailed? From $8 a month from Rx Outreach, by mail. Make a free account, then have your prescription sent there.
Open Rx OutreachA regular generic has the same active ingredient as Tenormin, and the FDA requires it to work the same way.
Tenormin, the original
We didn’t find a savings card or cash price from Tenormin’s maker. Ask the pharmacy for Tenormin’s cash price. With insurance, ask what your plan charges.
There isn’t one.
Same active ingredient as Tenormin. Fillers and dyes can differ.
Pharmacies’ own cash prices for generic atenolol, lowest first.
Pick up in storeDelivered
From each pharmacy’s own site, read November 17, 2026. Confirm the price before you fill.
Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.
8 companies sell a generic of Tenormin that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
Product page on aurobindousa.com
25 mg White to Off-white, round, 6 mm, marked “D / 21”
| Package | NDC |
|---|---|
| Bottle of 100 | 65862-168-01 |
| Bottle of 1000 | 65862-168-99 |
50 mg White to Off-white, round, 7 mm, marked “D / 22”
| Package | NDC |
|---|---|
| Bottle of 100 | 65862-169-01 |
| Bottle of 1000 | 65862-169-99 |
100 mg White to Off-white, round, 9 mm, marked “D / 23”
| Package | NDC |
|---|---|
| Bottle of 100 | 65862-170-01 |
| Bottle of 1000 | 65862-170-99 |
Inactive ingredients: sodium starch glycolate type a potato, crospovidone (120 .mu.m), povidone k90, microcrystalline cellulose, silicon dioxide, magnesium stearate
Product page on unichemusa.com
25 mg White, round, 6 mm, marked “RE / 19”
| Package | NDC |
|---|---|
| Bottle of 10 | 83980-022-97 |
| Bottle of 100 | 83980-022-01 |
| Bottle of 1000 | 83980-022-10 |
50 mg White, round, 7 mm, marked “RE / 20”
| Package | NDC |
|---|---|
| Bottle of 10 | 83980-023-97 |
| Bottle of 100 | 83980-023-01 |
| Bottle of 1000 | 83980-023-10 |
100 mg White, round, 9 mm, marked “RE / 21”
| Package | NDC |
|---|---|
| Bottle of 10 | 83980-024-97 |
| Bottle of 100 | 83980-024-01 |
| Bottle of 1000 | 83980-024-10 |
Inactive ingredients: magnesium carbonate, magnesium stearate, sodium lauryl sulfate, sodium starch glycolate type a potato, starch, corn, silicon dioxide
25 mg White to off-white, round, 6 mm, marked “M / A2”
| Package | NDC |
|---|---|
| Carton of 100 | 51079-759-20 |
50 mg White, round, 7 mm, marked “M / 231”
| Package | NDC |
|---|---|
| Carton of 100 | 51079-684-20 |
100 mg White, round, 9 mm, marked “M / 757”
| Package | NDC |
|---|---|
| Carton of 100 | 51079-685-20 |
Inactive ingredients: silicon dioxide, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, sodium starch glycolate type a potato
25 mg White to off-white, round, 6 mm, marked “M / A2”
| Package | NDC |
|---|---|
| Bottle of 100 | 0378-0218-01 |
| Bottle of 1000 | 0378-0218-10 |
50 mg White, round, 7 mm, marked “M / 231”
| Package | NDC |
|---|---|
| Bottle of 100 | 0378-0231-01 |
| Bottle of 1000 | 0378-0231-10 |
100 mg White, round, 9 mm, marked “M / 757”
| Package | NDC |
|---|---|
| Bottle of 100 | 0378-0757-01 |
| Bottle of 1000 | 0378-0757-10 |
Inactive ingredients: silicon dioxide, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, sodium starch glycolate type a potato
Made by Unique Pharmaceutical Laboratories
25 mg White, round, 6 mm, marked “ATN / 25”
| Package | NDC |
|---|---|
| Bottle of 100 | 64980-437-01 |
| Bottle of 1000 | 64980-437-10 |
50 mg White, round, 8 mm, marked “ATN / 50”
| Package | NDC |
|---|---|
| Bottle of 100 | 64980-438-01 |
| Bottle of 1000 | 64980-438-10 |
100 mg White, round, 10 mm, marked “ATN / 100”
| Package | NDC |
|---|---|
| Bottle of 100 | 64980-439-01 |
| Bottle of 1000 | 64980-439-10 |
Inactive ingredients: magnesium stearate, cellulose, microcrystalline, povidone, sodium starch glycolate type a potato, hypromelloses, titanium dioxide, glycerin
25 mg White to off-white marble, round, 6 mm, marked “787 / TEVA”
| Package | NDC |
|---|---|
| Bottle of 100 | 0093-0787-01 |
| Bottle of 1000 | 0093-0787-10 |
50 mg White to off-white marble, round, 7 mm, marked “93 / 752 / TEVA”
| Package | NDC |
|---|---|
| Bottle of 100 | 0093-0752-01 |
| Bottle of 1000 | 0093-0752-10 |
100 mg White to off-white marble, round, 9 mm, marked “753 / TEVA”
| Package | NDC |
|---|---|
| Bottle of 100 | 0093-0753-01 |
| Bottle of 500 | 0093-0753-05 |
Inactive ingredients: magnesium stearate, cellulose, microcrystalline, povidone k30, sodium starch glycolate type a potato
Product page on unichemusa.com
25 mg White to off white, capsule, 7 mm, marked “U / 22”
| Package | NDC |
|---|---|
| Bottle of 100 | 29300-410-01 |
| Bottle of 500 | 29300-410-05 |
| Bottle of 1000 | 29300-410-10 |
50 mg White to off white, round, 7 mm, marked “U / 2 / 1”
| Package | NDC |
|---|---|
| Bottle of 100 | 29300-411-01 |
| Bottle of 500 | 29300-411-05 |
| Bottle of 1000 | 29300-411-10 |
100 mg White to off white, round, 9 mm, marked “U / 20”
| Package | NDC |
|---|---|
| Bottle of 100 | 29300-412-01 |
| Bottle of 500 | 29300-412-05 |
| Bottle of 1000 | 29300-412-10 |
Inactive ingredients: magnesium stearate, microcrystalline cellulose, povidone k30, silicon dioxide, sodium starch glycolate type a potato
25 mg WHITE TO OFF- WHITE, round, 6 mm, marked “Z / 65”
| Package | NDC |
|---|---|
| Bottle of 90 | 68382-022-16 |
| Bottle of 100 | 68382-022-01 |
| Bottle of 1000 | 68382-022-10 |
| Bottle of 5000 | 68382-022-40 |
| Bottle of 10000 | 68382-022-24 |
50 mg WHITE TO OFF- WHITE, round, 8 mm, marked “Z / 66”
| Package | NDC |
|---|---|
| Bottle of 90 | 68382-023-16 |
| Bottle of 100 | 68382-023-01 |
| Bottle of 1000 | 68382-023-10 |
| Bottle of 2000 | 68382-023-02 |
| Bottle of 5000 | 68382-023-40 |
| Bottle of 10000 | 68382-023-24 |
100 mg WHITE TO OFF- WHITE, round, 10 mm, marked “Z / 67”
| Package | NDC |
|---|---|
| Bottle of 90 | 68382-024-16 |
| Bottle of 100 | 68382-024-01 |
| Bottle of 1000 | 68382-024-10 |
| Bottle of 5000 | 68382-024-40 |
Inactive ingredients: anhydrous citric acid, croscarmellose sodium, magnesium stearate, silicon dioxide, povidone, cellulose, microcrystalline
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
“Before you fill my Tenormin, can you tell me what I’d pay for the brand and for a generic?”
Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.
Hypertension
TENORMIN is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
TENORMIN may be administered with other antihypertensive agents.
Angina Pectoris Due to Coronary Atherosclerosis
TENORMIN is indicated for the long-term management of patients with angina pectoris.
Acute Myocardial Infarction
TENORMIN is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient’s clinical condition allows. (See DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS.) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit.
Source: the FDA label for Tenormin (Upsher-Smith Laboratories, LLC), September 18, 2025. Full label on DailyMed
Prices checked November 17, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/tenormin/